Cargando…
The clinical promise of immunotherapy in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a heterogeneous disease with poorer outcomes compared to other breast cancer subtypes. Contributing to the worse prognosis in TNBC is the higher rates of relapse and rapid progression after relapse. Advances in targeted therapeutics and conventional chemothera...
Autores principales: | Vikas, Praveen, Borcherding, Nicholas, Zhang, Weizhou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292225/ https://www.ncbi.nlm.nih.gov/pubmed/30573992 http://dx.doi.org/10.2147/CMAR.S185176 |
Ejemplares similares
-
Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
por: Wang, Xiaoxiao, et al.
Publicado: (2023) -
Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022) -
Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021) -
Natural and Synthetic Estrogens in Chronic Inflammation and Breast Cancer
por: Maharjan, Chandra K., et al.
Publicado: (2021) -
Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)